MCID: GLM007
MIFTS: 57

Glomerulonephritis

Categories: Blood diseases, Immune diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Glomerulonephritis

MalaCards integrated aliases for Glomerulonephritis:

Name: Glomerulonephritis 12 74 52 54 6 43 15 37 71
Bright's Disease 52

Classifications:



External Ids:

Disease Ontology 12 DOID:2921
MeSH 43 D005921
NCIt 49 C26784
SNOMED-CT 67 36171008
ICD10 32 N05 N08
UMLS 71 C0017658

Summaries for Glomerulonephritis

NIH Rare Diseases : 52 Glomerulonephritis is a type of kidney disease in which there is inflammation of the glomeruli, the tiny filters that remove excess waste and fluids from the blood. It may be acute or chronic (coming on gradually), and may occur on its own (primary) or be caused by another condition (secondary). Signs and symptoms may depend on the type and cause of the condition and may include blood in the urine; foamy urine; swelling of the face, eyes, or other body parts; abdominal pain; high blood pressure ; fatigue; and/or other symptoms. If the condition is severe or prolonged, the kidneys can become damaged. It may be caused by a variety of infections and diseases, and sometimes the cause is unknown. Treatment depends on the cause, type and severity of the condition.

MalaCards based summary : Glomerulonephritis, also known as bright's disease, is related to mesangial proliferative glomerulonephritis and crescentic glomerulonephritis. An important gene associated with Glomerulonephritis is CFHR5 (Complement Factor H Related 5), and among its related pathways/superpathways are Innate Immune System and Folate Metabolism. The drugs Candesartan cilexetil and Ramipril have been mentioned in the context of this disorder. Affiliated tissues include Kidney, neutrophil and t cells, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

Disease Ontology : 12 A nephritis that causes inflammation of the glomeruli located in kidney.

Wikipedia : 74 Glomerulonephritis (GN) is a term used to refer to several kidney diseases (usually affecting both... more...

Related Diseases for Glomerulonephritis

Diseases in the Glomerulonephritis family:

Autoimmune Glomerulonephritis Subacute Glomerulonephritis

Diseases related to Glomerulonephritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1194)
# Related Disease Score Top Affiliating Genes
1 mesangial proliferative glomerulonephritis 34.8 CD79A CD40LG CCL2
2 crescentic glomerulonephritis 34.6 PRTN3 MPO CCL2
3 proliferative glomerulonephritis 34.5 MPO CR1 CFH CCL2 C3
4 membranoproliferative glomerulonephritis 34.5 NPHS1 CFP CFHR5 CFH CD79A C4A
5 diffuse glomerulonephritis 34.5 CFP C3
6 rapidly progressive glomerulonephritis 34.4 PRTN3 MPO COL4A3 CFP CD40LG C3
7 nephrotic syndrome, type 7 34.4 CFI CFHR5 CFH
8 dense deposit disease 34.4 CFHR5 CFH C3
9 c3 glomerulopathy 34.4 CFP CFI CFHR5 CFH C3
10 anti-basement membrane glomerulonephritis 34.3 PRTN3 MPO COL4A5 COL4A3 ALB
11 iga glomerulonephritis 34.3 NPHS1 CFHR5 CFH CD79A CD40LG C3
12 immune-complex glomerulonephritis 34.3 MPO CFI CD40LG C4B ALB
13 complement factor h deficiency 34.2 CFI CFHR5 CFH
14 acute proliferative glomerulonephritis 34.1 PRTN3 NPHS1 MPO COL4A3 CD40LG CCL2
15 acute poststreptococcal glomerulonephritis 34.1 CFP CFHR5 CD79A CD40LG C3 ALB
16 membranous nephropathy 34.0 NPHS1 MPO LRP2 CD79A C3 ALB
17 iga nephropathy 1 33.7 NPHS1 CD79A
18 goodpasture syndrome 33.5 PRTN3 NPHS1 MPO COL4A5 COL4A3 CD40LG
19 alport syndrome 33.3 COL4A5 COL4A3 CFH ALB
20 henoch-schoenlein purpura 33.2 PRTN3 MPO CD79A CD40LG
21 lipoid nephrosis 32.9 NPHS1 CD79A CD40LG CCL2 ALB
22 complement factor i deficiency 32.9 CR1 CFP CFI C4B C3
23 granulomatosis with polyangiitis 32.3 PRTN3 MPO CD40LG
24 systemic lupus erythematosus 32.2 PRTN3 MPO CR1 CFI CFH CD79A
25 acute kidney failure 32.1 PRTN3 CFH ALB
26 purpura 32.0 CD79A CD40LG C3
27 anca-associated vasculitis 32.0 PRTN3 MPO C3
28 vasculitis 31.9 PRTN3 MPO CD79A CD40LG CCL2 C3
29 thrombotic microangiopathy 31.8 CFI CFH
30 autoimmune disease 31.7 PRTN3 CD79A CD40LG CCL2 C3
31 glomerular disease 31.7 NPHS1 COL4A5 CD79A CCL2 ALB
32 lupus erythematosus 31.7 CR1 CD40LG C4B C4A C3 C1S
33 focal segmental glomerulosclerosis 31.6 NPHS1 COL4A5 COL4A3 ALB
34 hydrops, lactic acidosis, and sideroblastic anemia 31.5 MPO C1S ALB
35 exanthem 31.4 PRTN3 CD40LG ALB
36 churg-strauss syndrome 31.3 PRTN3 MPO CD40LG
37 kidney disease 31.3 PRTN3 NPHS1 COL4A5 COL4A3 CFH CD79A
38 hemolytic anemia 31.3 CR1 CFI CFH CD40LG C3
39 hemolytic-uremic syndrome 31.3 CFI CFHR5 CFH CD40LG C4B C3
40 pulmonary hemosiderosis 31.3 PRTN3 MPO
41 syphilis 31.3 CD79A CD40LG ALB
42 proteasome-associated autoinflammatory syndrome 1 31.2 MPO CCL2 ALB
43 nephrosclerosis 31.2 NPHS1 MPO CCL2
44 subacute bacterial endocarditis 31.2 PRTN3 MPO CD40LG
45 arteriolosclerosis 31.1 CD79A C3 ALB
46 acute kidney tubular necrosis 31.1 LRP2 CD40LG ALB
47 pneumonia 31.1 MPO CR1 CD40LG CCL2 ALB
48 complement component 2 deficiency 31.0 CFH C4B C4A
49 diarrhea 31.0 MPO CD40LG C3 ALB
50 immunoglobulin alpha deficiency 31.0 CD79A CD40LG C4A

Graphical network of the top 20 diseases related to Glomerulonephritis:



Diseases related to Glomerulonephritis

Symptoms & Phenotypes for Glomerulonephritis

GenomeRNAi Phenotypes related to Glomerulonephritis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.28 ALB C1QC C3 C4A CCL2 CD79A

MGI Mouse Phenotypes related to Glomerulonephritis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.97 ALB C3 C4B CD40LG CD79A CFH
2 cardiovascular system MP:0005385 9.96 ALB C3 C4B CD40LG CFH CFP
3 immune system MP:0005387 9.77 ALB C3 C4B CCL2 CD40LG CD79A
4 renal/urinary system MP:0005367 9.36 ALB C3 C4B CD40LG CD79A CFH

Drugs & Therapeutics for Glomerulonephritis

Drugs for Glomerulonephritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 259)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
2
Ramipril Approved Phase 4 87333-19-5 5362129
3
Losartan Approved Phase 4 114798-26-4 3961
4
Probucol Approved, Investigational Phase 4 23288-49-5 4912
5
Hydroxychloroquine Approved Phase 4 118-42-3 3652
6
Bortezomib Approved, Investigational Phase 4 179324-69-7 387447 93860
7
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
8
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
9
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
10
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
11
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
12
Basiliximab Approved, Investigational Phase 4 179045-86-4, 152923-56-3
13
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
14
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
15
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
16
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
17
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
18
Cilnidipine Investigational Phase 4 132203-70-4 5282138
19
Candesartan Experimental Phase 4 139481-59-7 2541
20
Dexchlorpheniramine Experimental, Investigational Phase 4 25523-97-1 33036
21 Anti-Arrhythmia Agents Phase 4
22 Mitogens Phase 4
23 interferons Phase 4
24 Interferon-alpha Phase 4
25 Adrenergic alpha-Antagonists Phase 4
26 calcium channel blockers Phase 4
27 Cassava Phase 4
28 Anticholesteremic Agents Phase 4
29 Serine Proteinase Inhibitors Phase 4
30 Omega 3 Fatty Acid Phase 4
31 Antimalarials Phase 4
32 Antiparasitic Agents Phase 4
33 Antiprotozoal Agents Phase 4
34 Proteasome Inhibitors Phase 4
35 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,... Phase 4
36 Sodium-Glucose Transporter 2 Inhibitors Phase 4
37 Anticonvulsants Phase 4
38 Sodium Chloride Symporter Inhibitors Phase 4
39 Carbonic Anhydrase Inhibitors Phase 4
40 Estrogens Phase 4
41 Estrogens, Conjugated (USP) Phase 4
42 Calcineurin Inhibitors Phase 4
43 Antifungal Agents Phase 4
44 Dermatologic Agents Phase 4
45 Cyclosporins Phase 4
46 Endorphins Phase 4
47 Pharmaceutical Solutions Phase 4
48 Histamine H1 Antagonists Phase 4
49 Histamine Antagonists Phase 4
50 Antihypertensive Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 296)
# Name Status NCT ID Phase Drugs
1 A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy Unknown status NCT01184599 Phase 4 aliskiren
2 Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis—a Multicentre, Prospective, Double-blind, Double-dummy, Randomized Controlled Clinical Trial Unknown status NCT02063100 Phase 4 Shenyankangfu tablets;Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 100mg;Losartan potassium 100mg
3 Calcitriol in the Treatment of Immunoglobulin A Nephropathy Unknown status NCT00862693 Phase 4 Calcitriol
4 A Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Unknown status NCT01758120 Phase 4 prednisone plus cyclophosphamide;Prednisone alone
5 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study Unknown status NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
6 Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients Unknown status NCT00541853 Phase 4 Candesartan;Candesartan and Cilnidipine;Candesartan plus non-CCB agents
7 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
8 A Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation Pathology Unknown status NCT02571842 Phase 4 Intravenous Rituximab;ACEI/ARB and corticosteroids
9 Multi-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA Nephropathy Unknown status NCT02981212 Phase 4 Mycophenolate Mofetil;ACE inhibitor;Corticosteroid;ARB
10 Calcineurin Inhibitor Minimisation in Renal Transplant Recipients With Stable Allograft Function: A Prospective Randomised Controlled Trial Unknown status NCT00541814 Phase 4 Cyclosporine
11 A Prospective Randomized, Controlled, Double Blinded Trial of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy Completed NCT00426348 Phase 4 Valsartan;Probucol;Placebo
12 Mycophenolate Mofetil and Tacrolimus vs Tacrolimus Alone for the Treatment of Idiopathic Membranous Glomerulonephritis (IMG) Completed NCT00843856 Phase 4 tacrolimus;tacrolimus and mycophenolate mofetil
13 Long-term Treatment by Inhibitors of Angiotensin II at Low Doses in Non-nephrotic Proteinuric Patients With Pauciimmune and IgA Mesangioproliferative Glomerulonephritis Completed NCT01115426 Phase 4 Ramipril or losartan
14 Low-dose Combination of Mycophenolate Mofetil and Tacrolimus for Refractory Lupus Nephritis: a 12-month Prospective Study Completed NCT01203709 Phase 4 low dose combination of MMF and Tac
15 Open-Label, Randomized, Comparative, Multi-Center Clinical Trial on the Therapeutic Effect of Tacrolimus (Prograf Cap.®) in Combination With Low-Dose Corticosteroid Compared With High-Dose Corticosteroid Alone in Patients With Minimal-Change Nephrotic Syndrome (MCNS) Completed NCT01763580 Phase 4 Tacrolimus;Prednisolone
16 Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Completed NCT01206569 Phase 4 Long-acting tacrolimus (Advagraf, Astellas Pharma)
17 HSP-glomerulonephritis Trial: MP vs CyA Completed NCT00425724 Phase 4 Methylprednisolone pulses plus prednisone versus Cyclosporine A
18 To Compare the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis Completed NCT00371319 Phase 4 tacrolimus;mycophenolate mofetil
19 Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy Completed NCT00367562 Phase 4 ENALAPRIL VALSARTAN METHYLPREDNISONE
20 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis Completed NCT00125307 Phase 4 tacrolimus
21 To Compare the Efficacy and Safety of TW vs Valsartan in the MN Completed NCT00518219 Phase 4 TW
22 Aliskiren Combined With Losartan in Immunoglobulin A Nephropathy: an Open-label Pilot Study Completed NCT00922311 Phase 4 Aliskiren
23 Renal Division, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease Completed NCT02351752 Phase 4 Hydroxychloroquine Sulfate
24 A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN) Completed NCT01386554 Phase 4 Repository Corticotropin Injection;Placebo
25 Velcade Therapy for Severe IgA Nephropathy Completed NCT01103778 Phase 4 Bortezomib (Velcade®)
26 A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy Completed NCT00498368 Phase 4 Intravenous Rituximab;ACE/ARB
27 Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects: "The TRANSLATE Study" Completed NCT02585804 Phase 4 Dapagliflozin
28 Tacrolimus vs Prednisolone for the Treatment Minimal Change Disease Completed NCT00982072 Phase 4 tacrolimus;prednisolone
29 The Safety and Short-Term Efficacy of Calcitriol in the Treatment of Immunoglobulin A Nephropathy Completed NCT00319761 Phase 4 Calcitriol
30 Corticosteroids and Azathioprine Versus Corticosteroids Alone in IgA Nephropathy: a Randomized Controlled Trial. Completed NCT00755859 Phase 4 steroids plus azathioprine;steroids
31 Acetazolamide and Hydrochlorothiazide Followed by Furosemide Versus Hydrochlorothiazide and Furosemide Followed by Furosemide for the Treatment of Adults With Refractory Nephrotic Edema: A Randomized, Double-Blind Trial Completed NCT02427880 Phase 4 Acetazolamide and Hydrochlorothiazide Followed by Furosemide;Furosemide and Hydrochlorothiazide Followed by Furosemide
32 A Prospective, Randomized, Open Label, Case-Controlled Study on the Efficacy of Mycophenolate Mofetil for IgA Nephropathy Patients With Heavy Proteinuria Despite Angiotensin Blockade Completed NCT00863252 Phase 4 mycophenolate mofetil;angiotensin blockade
33 Effect Of Hormone Replacement Therapy On Disease Activity, Menopausal Symptoms And Bone Mineral Density In Peri/Postmenopausal Women With Systemic Lupus Erythematosus.Randomized Clinical Trial Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
34 Immunoadsorption in Anti-glomerular Basement Membrane Glomerulonephritis; a Pilot Study Recruiting NCT02765789 Phase 4
35 Changes in Autoreactive Memory B Cells as Biomarker of Response to Adrenocorticotropic Hormone in Patients With Membranous Nephropathy Recruiting NCT03025828 Phase 4 ACTHar
36 The Therapy of Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis : A Multicenter, Prospective, Randomized, Controlled, Single-blind Trial. Recruiting NCT03062813 Phase 4 Tacrolimus &entecavir;placebo & entecavir
37 A Prospective Randomized, Controlled Trial of Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy Recruiting NCT03170323 Phase 4 Mycophenolate Mofetil;Cyclosporins
38 A Multicenterer, Comparative Safety Andof ACTHar Gel Alone or in Cwith oe Urinary in Patients Positive Fibrillary Glomerulopathy Recruiting NCT04080076 Phase 4 Acthar 80 UNT/ML Injectable Solution;Tacrolimus capsule
39 Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment Active, not recruiting NCT02523768 Phase 4 ATG-F;Simulect
40 An Extended Follow-up of the Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced Stage IgA Nephropathy Active, not recruiting NCT03218852 Phase 4 prednisone and cyclophosphamide;prednisone alone
41 A Randomized, Controlled Trial to Evaluate Leflunomide Plus Low Dose Corticosteroid Therapy in Progressive IgA Nephropathy With Renal Insufficiency Not yet recruiting NCT04020328 Phase 4 Leflunomide 20 mg+prednisone 0.5mg/kg/d
42 Effect of Immunosuppression in IgA Nephropathy Not yet recruiting NCT03468972 Phase 4 Immunosuppressive treatment
43 Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease Terminated NCT01129557 Phase 4 Aliskiren;Valsartan
44 An Open Label Randomized Phase IV Study of the Safety and Efficacy of ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis Withdrawn NCT01926054 Phase 4 Acthar gel
45 The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria Withdrawn NCT00508898 Phase 4 Calcitriol;Multivitamin
46 Impact of Acthar on Proteinuria and Disease Progression in IgA Nephropathy Patients With Nephrotic Range Proteinuria Withdrawn NCT02382523 Phase 4 Acthar 80 unit injection
47 A Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous Nephropathy Unknown status NCT01282073 Phase 3 Mycophenolate mofetil, low dose steroid;Cyclosporin, low dose steroid
48 Effect of Rituximab in Treatment of Primary Membranoproliferative Glomerulonephritis Unknown status NCT03180723 Phase 3 Rituximab;Cyclosporin
49 Phase 3 Study of Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f Unknown status NCT02187900 Phase 3 Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH);Mycophenolate mofetil (MMF)
50 Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy —— A Prospective, Randomized, Controlled, Multi-Center Clinical Trial Unknown status NCT02662283 Phase 2, Phase 3 Prednisolone;Reh-acteoside

Search NIH Clinical Center for Glomerulonephritis

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Glomerulonephritis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Glomerulonephritis:
Mesenchymal stromal cells for glomerulonephritis
Embryonic/Adult Cultured Cells Related to Glomerulonephritis:
Bone marrow-derived mesenchymal stromal cells PMIDs: 22172807

Cochrane evidence based reviews: glomerulonephritis

Genetic Tests for Glomerulonephritis

Anatomical Context for Glomerulonephritis

The Foundational Model of Anatomy Ontology organs/tissues related to Glomerulonephritis:

19
Kidney

MalaCards organs/tissues related to Glomerulonephritis:

40
Kidney, Neutrophil, T Cells, Liver, B Cells, Endothelial, Monocytes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Glomerulonephritis:
# Tissue Anatomical CompartmentCell Relevance
1 Kidney Glomerulus Affected by disease

Publications for Glomerulonephritis

Articles related to Glomerulonephritis:

(show top 50) (show all 27388)
# Title Authors PMID Year
1
Suppression of nephrin expression by TNF-alpha via interfering with the cAMP-retinoic acid receptor pathway. 54 61
20237236 2010
2
Regulation of myeloperoxidase-specific T cell responses during disease remission in antineutrophil cytoplasmic antibody-associated vasculitis: the role of Treg cells and tryptophan degradation. 54 61
20155828 2010
3
T cells, adhesion molecules and modulation of apoptosis in visceral leishmaniasis glomerulonephritis. 54 61
20459816 2010
4
Autoimmune kidney diseases. 54 61
19906361 2010
5
Is presence of ANCA in crescentic IgA nephropathy a coincidence or novel clinical entity? A case series. 54 61
20042261 2010
6
Differential deposition of C4d and MBL in glomeruli of patients with ANCA-negative pauci-immune crescentic glomerulonephritis. 54 61
19898926 2010
7
Ameliorative effects of arctiin from Arctium lappa on experimental glomerulonephritis in rats. 54 61
19524415 2009
8
Parallel genotyping of 10,204 single nucleotide polymorphisms to screen for susceptible genes for IgA nephropathy. 54 61
19890582 2009
9
[Expression of MCP-1 in renal tissues of patients with IgA nephropathy]. 54 61
19893256 2009
10
Hepatitis B virus associated focal and segmental glomerular sclerosis: report of two cases and review of literature. 54 61
19169768 2009
11
Resolution of IgM nephropathy after rituximab treatment. 54 61
19084309 2009
12
Analyzing antibody activity in IgA nephropathy. 54 61
19504718 2009
13
Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. 54 61
19067130 2009
14
Molecular heterogeneity of urinary albumin in glomerulonephritis: comparison of cardiovascular disease with albuminuria. 54 61
19150611 2009
15
Experimental autoimmune vasculitis: an animal model of anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis. 54 61
19264905 2009
16
Monocyte chemoattractant protein 1 is a prognostic marker in ANCA-associated small vessel vasculitis. 54 61
19587833 2009
17
Vasculitic IgA nephropathy: prognosis and outcome. 54 61
19342865 2009
18
Transforming growth factor-beta 1 in Balkan endemic nephropathy. 54 61
19147994 2009
19
[MPO-positive cells and extracellular MPO in the glomeruli of MPO-ANCA-associated glomerulonephritis]. 54 61
19238910 2009
20
Glomerular diseases in a Hispanic population: review of a regional renal biopsy database. 54 61
19820874 2009
21
A comparative study of the diagnostic accuracy of ELISA systems for the detection of anti-neutrophil cytoplasm antibodies available in Japan and Europe. 54 61
19210866 2008
22
The protective role of uteroglobin through the modulation of tissue transglutaminase in the experimental crescentic glomerulonephritis. 54 61
18558621 2008
23
Valvular injury in a patient with PR3-ANCA-associated glomerulonephritis. 54 61
18762796 2008
24
Antigenic heterogeneity of IgA anti-GBM disease: new renal targets of IgA autoantibodies. 54 61
18752876 2008
25
Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. 54 61
18725016 2008
26
[Crohn's disease in association with IgA nephropathy]. 54 61
19077504 2008
27
IgA nephropathy: lessons from an animal model, the ddY mouse. 54 61
18651534 2008
28
Deletion of IL-18 receptor ameliorates renal injury in bovine serum albumin-induced glomerulonephritis. 54 61
18462998 2008
29
Human neutrophil Fcgamma receptors initiate and play specialized nonredundant roles in antibody-mediated inflammatory diseases. 54 61
18538590 2008
30
Increased plasma acylation-stimulating protein in pediatric proteinuric renal disease. 54 61
18253759 2008
31
Scleroderma with crescentic glomerulonephritis: a case report. 54 61
18474117 2008
32
Smad7 as a therapeutic agent for chronic kidney diseases. 54 61
18508563 2008
33
Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits. 54 61
18371543 2008
34
Pathological regression by angiotensin II type 1 receptor blockade in patients with mesangial proliferative glomerulonephritis. 54 61
18497456 2008
35
Should a renal biopsy be performed at the first relapse of 'clinical nephrotic syndrome'? 54 61
18365928 2008
36
Diagnostic value of the aminopeptidase N, N-acetyl-beta-D-glucosaminidase and dipeptidylpeptidase IV in evaluating tubular dysfunction in patients with glomerulopathies. 54 61
18925530 2008
37
Role of macrophage migration inhibition factor in kidney disease. 54 61
18663334 2008
38
Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. 54 61
17914026 2008
39
Remission of proteinuria improves prognosis in IgA nephropathy. 54 61
17978307 2007
40
The monocyte chemoattractant protein-1/cognate CC chemokine receptor 2 system affects cell motility in cultured human podocytes. 54 61
18055544 2007
41
Intramolecular epitope spreading in Heymann nephritis. 54 61
18003776 2007
42
Chemically modified siRNA prolonged RNA interference in renal disease. 54 61
17880921 2007
43
Streptococcal exotoxin B increases interleukin-6, tumor necrosis factor alpha, interleukin-8 and transforming growth factor beta-1 in leukocytes. 54 61
17530297 2007
44
Perioperative management of MYH9 hereditary macrothrombocytopenia (Fechtner syndrome). 54 61
17655694 2007
45
Lack of association between NPHS2 gene polymorphisms and sporadic IgA nephropathy. 54 61
17635752 2007
46
Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. 54 61
17342176 2007
47
Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis. 54 61
17205957 2007
48
PDGF-B gene single-nucleotide polymorphisms are not predictive for disease onset or progression of IgA nephropathy. 54 61
17338425 2007
49
Association between the clara cell secretory protein (CC16) G38A polymorphism and the progression of IgA nephropathy. 54 61
17338426 2007
50
Chemokines and chemokine receptors in glomerulonephritis and renal allograft rejection. 54 61
17261994 2007

Variations for Glomerulonephritis

ClinVar genetic disease variations for Glomerulonephritis:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CEL NM_001807.5(CEL):c.1966G>C (p.Ala656Pro)SNV Uncertain significance 128688 rs587780309 9:135946855-135946855 9:133071468-133071468

Copy number variations for Glomerulonephritis from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 21052 1 156500000 165500000 Copy number FCGR3 Glomerulonephritis
2 21055 1 156500000 165500000 Loss FCGR3B Glomerulonephritis
3 21056 1 156500000 165500000 Low copy number FCGR3B Glomerulonephritis

Expression for Glomerulonephritis

Search GEO for disease gene expression data for Glomerulonephritis.

Pathways for Glomerulonephritis

Pathways related to Glomerulonephritis according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 PRTN3 MPO CR1 CFP CFI CFH
2
Show member pathways
12.11 MPO LRP2 CCL2 ALB
3
Show member pathways
12.02 CR1 CFI CFH C4B C4A C3
4 11.85 CFI CFH C4B C4A C3 C1S
5
Show member pathways
11.78 CR1 CFP CFH C4B C4A C3
6 11.77 CR1 CFI CFHR5 CFH C4B C4A
7 11.67 COL4A5 COL4A3 CCL2
8 11.65 C4B C4A C3 C1S C1QC
9 11.6 NPHS1 CR1 COL4A5 COL4A3
10
Show member pathways
11.4 CR1 CFP CFI CFH C4B C4A
11 11.33 CR1 CD40LG CCL2

GO Terms for Glomerulonephritis

Cellular components related to Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.06 PRTN3 NPHS1 MPO LRP2 CR1 CFI
2 extracellular region GO:0005576 9.86 PRTN3 MPO COL4A5 COL4A3 CFP CFI
3 collagen-containing extracellular matrix GO:0062023 9.77 PRTN3 COL4A5 COL4A3 CFP C1QC
4 endoplasmic reticulum lumen GO:0005788 9.73 COL4A5 COL4A3 CFP C4A C3 ALB
5 blood microparticle GO:0072562 9.7 CFH C4B C4A C3 C1S C1QC
6 collagen trimer GO:0005581 9.63 COL4A5 COL4A3 C1QC
7 azurophil granule lumen GO:0035578 9.61 PRTN3 MPO C3
8 extracellular space GO:0005615 9.5 PRTN3 MPO COL4A5 COL4A3 CFP CFI
9 collagen type IV trimer GO:0005587 9.4 COL4A5 COL4A3

Biological processes related to Glomerulonephritis according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.97 CR1 CFP CFI CFH C4B C4A
2 immune response GO:0006955 9.91 CFP CD40LG CCL2 C3 C1QC
3 neutrophil degranulation GO:0043312 9.88 PRTN3 MPO CR1 CFP C3
4 inflammatory response GO:0006954 9.83 CD40LG CCL2 C4B C4A C3
5 complement activation, classical pathway GO:0006958 9.8 CR1 CFI C4B C4A C3 C1S
6 negative regulation of endopeptidase activity GO:0010951 9.71 COL4A3 C4B C4A C3
7 complement activation, alternative pathway GO:0006957 9.67 CFP CFHR5 CFH C3
8 amyloid-beta clearance GO:0097242 9.52 LRP2 C3
9 complement activation GO:0006956 9.5 CFP CFH C4B C4A C3 C1S
10 collagen-activated tyrosine kinase receptor signaling pathway GO:0038063 9.49 COL4A5 COL4A3
11 glomerular basement membrane development GO:0032836 9.46 NPHS1 COL4A3
12 positive regulation of apoptotic cell clearance GO:2000427 9.46 CCL2 C4B C4A C3
13 regulation of complement activation GO:0030449 9.32 CR1 CFP CFI CFHR5 CFH C4B

Molecular functions related to Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endopeptidase inhibitor activity GO:0004866 8.8 C4B C4A C3

Sources for Glomerulonephritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....